214 related articles for article (PubMed ID: 23558673)
1. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer.
Boda-Heggemann J; Weiss C; Schneider V; Hofheinz RD; Haneder S; Michaely H; Wertz H; Ronellenfitsch U; Hochhaus A; Wenz F; Lohr F
Strahlenther Onkol; 2013 May; 189(5):417-23. PubMed ID: 23558673
[TBL] [Abstract][Full Text] [Related]
2. Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer.
Boda-Heggemann J; Hofheinz RD; Weiss C; Mennemeyer P; Mai SK; Hermes P; Wertz H; Post S; Massner B; Hieber U; Hochhaus A; Wenz F; Lohr F
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1187-95. PubMed ID: 19409725
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
4. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
Dewas CV; Maingon P; Dalban C; Petitfils A; Peignaux K; Truc G; Martin E; Khoury C; Dewas S; Créhange G
Radiat Oncol; 2012 Nov; 7():201. PubMed ID: 23190693
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Haller DG; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Gilberg F; Rittweger K; Schmoll HJ
J Clin Oncol; 2011 Apr; 29(11):1465-71. PubMed ID: 21383294
[TBL] [Abstract][Full Text] [Related]
6. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.
Glynne-Jones R; Counsell N; Quirke P; Mortensen N; Maraveyas A; Meadows HM; Ledermann J; Sebag-Montefiore D
Ann Oncol; 2014 Jul; 25(7):1356-1362. PubMed ID: 24718885
[TBL] [Abstract][Full Text] [Related]
7. Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence.
Yuan ST; Wang FL; Liu N; Liu YH; Liu SG; Huang Y; Li YQ; Liu XB; Zhang Y; Li WH; Yu J; Zhang JD
Am J Clin Oncol; 2015 Apr; 38(2):130-4. PubMed ID: 23608834
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis.
Ren F; Li S; Zhang Y; Zhao Z; Wang H; Cui Y; Wang M
Radiat Oncol; 2019 May; 14(1):84. PubMed ID: 31118042
[TBL] [Abstract][Full Text] [Related]
9. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer.
Minn AY; Hsu A; La T; Kunz P; Fisher GA; Ford JM; Norton JA; Visser B; Goodman KA; Koong AC; Chang DT
Cancer; 2010 Aug; 116(16):3943-52. PubMed ID: 20564136
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.
Wang X; Shen Y; Zhu H; Zhao Y; Li Z; Qiu M; Li Q; Gou H; Yang Y; Cao D; Liu J; Yi C; Liao Z; Luo D; Bi F; Xu F
Gastric Cancer; 2016 Jan; 19(1):245-54. PubMed ID: 25609451
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study.
Wang F; Qu A; Sun Y; Zhang J; Wei B; Cui Y; Liu X; Tian W; Li Y
Br J Radiol; 2021 Aug; 94(1124):20201088. PubMed ID: 34260297
[TBL] [Abstract][Full Text] [Related]
12. IMRT vs. 2D-radiotherapy or 3D-conformal radiotherapy of nasopharyngeal carcinoma : Survival outcome in a Korean multi-institutional retrospective study (KROG 11-06).
Moon SH; Cho KH; Lee CG; Keum KC; Kim YS; Wu HG; Kim JH; Ahn YC; Oh D; Lee JH
Strahlenther Onkol; 2016 Jun; 192(6):377-85. PubMed ID: 26972085
[TBL] [Abstract][Full Text] [Related]
13. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Chun SG; Hu C; Choy H; Komaki RU; Timmerman RD; Schild SE; Bogart JA; Dobelbower MC; Bosch W; Galvin JM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Raben A; Augspurger ME; MacRae RM; Paulus R; Bradley JD
J Clin Oncol; 2017 Jan; 35(1):56-62. PubMed ID: 28034064
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.
Fuse N; Bando H; Chin K; Ito S; Yoshikawa T; Tsuburaya A; Terashima M; Kawashima Y; Fukunaga T; Gotoh M; Emi Y; Yoshida K; Oki E; Takahashi S; Kuriki H; Sato K; Sasako M
Gastric Cancer; 2017 Mar; 20(2):332-340. PubMed ID: 26956689
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of IMRT for breast cancer: a single-institution cohort analysis.
McDonald MW; Godette KD; Butker EK; Davis LW; Johnstone PA
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1031-40. PubMed ID: 18440727
[TBL] [Abstract][Full Text] [Related]
16. [Short-term efficacy comparison between preoperative three dimensional conformal radiotherapy and volumetric modulated arc therapy concurrently combined with chemotherapy in the treatment of locally advanced rectal carcinoma].
Xiao L; Yu X; Zhu Y; Xiao W; Zeng Z; Liu M; Zhang R; Gao Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jul; 19(7):769-75. PubMed ID: 27452754
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Wang Y; Zhuang RY; Yu YY; Yu S; Hou J; Ji Y; Sun YH; Shen KT; Shen ZB; Liu FL; Zhao NQ; Liu TS
Oncotarget; 2016 Nov; 7(46):76298-76307. PubMed ID: 27602586
[TBL] [Abstract][Full Text] [Related]
18. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
19. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.
Wu Y; Wei ZW; He YL; Schwarz RE; Smith DD; Xia GK; Zhang CH
World J Gastroenterol; 2013 Jun; 19(21):3309-15. PubMed ID: 23745033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
